XYWAV is the first and only FDA-approved medication to treat IH in adults. XYWAV has been studied across multiple symptoms of IH, such as excessive daytime sleepiness, sleep inertia, …

Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, and idiopathic hypersomnia (IH). Includes Xywav side effects, interactions …

Xywav is also approved to treat excessive daytime sleepiness and cataplexy (sudden muscle weakness) related to narcolepsy. Side effects of Xywav when used to treat these narcolepsy …

Learn about the multiple symptoms of IH like excessive daytime sleepiness and sleep inertia. See full Prescribing Information & BOXED Warning about serious side effects, CNS depression, …

Xywav was originally FDA-approved in 2002 to treat excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness triggered by strong emotions) in people at least 7 years …

For years, idiopathic hypersomnia, a neurologic sleep disorder characterized by chronic excessive daytime sleepiness (EDS), was treated with off-label wake-promoting therapies. In August …

Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 …

Conclusion Xywav represents a significant advancement in the treatment of narcolepsy and excessive daytime sleepiness. Its unique formulation offers effective symptom management …

XYWAV oral solution, 0.5 g/mL total salts (equivalent to 0.413 g/mL of oxybate) is the only FDA‑approved treatment for cataplexy and/or excessive daytime sleepiness in narcolepsy and …

Xywav is indicated for the treatment of excessive daytime sleepiness or cataplexy in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia.